Now reading Entry 030 / 102 Last revised Jan 22, 2026 35 sources 1 comparisons Methodology →
A specimen of the Repair & Recovery drawer Drawer B · Repair & Recovery

GHK-Cu

Research Only

A naturally occurring copper-binding tripeptide with wound healing and skin regeneration properties. Extensively studied globally with moderate-to-high evidence for cosmetic applications.

Copper Peptide GHK · Glycyl-L-Histidyl-L-Lysine:Copper

Research evidence
Moderate

10 human studies

Preclinical
46%
Clinical
29%

Based on 35 cited sources

Evidence Score68/100
Emerging / moderate
Research Depth56/100
Mechanism72/100
Plausibility71/100
Global Coverage70/100
Community Experience82/100
Effectiveness43/100

clinically demonstrated · low confidence

Demonstrated effect magnitude — not a recommendation or safety claim.

Research Depth 56 (1A 20: multiple small controlled/observational topical cosmetic skin studies, no adequately-powered RCT; 1B 9: best human evidence at "some concerns"/manufacturer-affiliated cosmetic trials, not low-RoB RCTs; 1C 6: total human N ~50-300; 1D 12: topical cosmetic outcomes directly match the claimed use; 1E 9: extensive replicated preclinical program across in-vitro, rat 11121126, mouse 27517151, pig, dog, zebrafish and C. elegans models). Mechanism 72 (2A 30: copper-cofactor delivery to lysyl oxidase / SOD with functional confirmation, plus TGF-beta pathway activation 22937864; 2B 20: wound-healing cascade SPARC->chemoattraction->TGF-beta->collagen->LOX crosslinking largely mapped; 2C 13: dose-response in >=2 models incl in vivo; 2D 9: confirmed in mammalian in-vivo models). Plausibility 71 (3A 28: mechanism->surrogate collagen/skin-density established, surrogate->cosmetic benefit shown 18644225; 3B 22: coherent with copper-enzyme and skin-remodeling biology; 3C 13: same-class copper/cofactor analogy support; 3D 8: deduction for broad "master regulator / 4,000 genes" multi-system claims). Global Coverage 70 (4A 28: reproduced across many independent groups; 4B 22: many countries - France, Korea, US, China, Poland; 4C 20: ~35 cited studies, diverse contexts; 4D 0: cosmetic ingredient, no drug-regulator approval). Community Experience 82 (5A 28: large skincare/anti-aging use; 5B 26: >7 yr sustained cosmetic use; 5C 15: broadly consistent reports; 5D 13: no notable recurring adverse signal topically). Effectiveness clinical/low: human cosmetic trials show statistically significant but modest firmness/wrinkle/ photodamage improvement at 12 weeks (E1 12 / E2 11 / E3 8 / E4 12 = 43); confidence low given small, often manufacturer-affiliated cosmetic studies.

Scored June 2026 How we rate →
~
Evidence Level
moderate
Not approved for human use by any regulatory agency
Limited human clinical trial data
Consult a healthcare provider before use
Not FDA Approved WADA Prohibited
Identity
SCALE · 1:1 N-TERMINUS C-TERMINUS 3 AA · 403.88 Da (copper complex)
Also Known As
Copper Peptide GHK • Glycyl-L-Histidyl-L-Lysine:Copper
Class
Tripeptide-Copper Complex
Length
3 amino acids
Mol. weight
403.88 Da (copper complex)
Sequence
GHK-Cu
Molecular Structure
G
H
K
Hydrophobic
Polar
Positive
Negative

GHK-Cu is a naturally occurring tripeptide that acts as a master regulator of tissue repair and regeneration. It is released from damaged collagen and serves as a signaling molecule that coordinates healing processes.

How It Works (Simplified)

GHK-Cu functions as a naturally occurring repair signal through several pathways:

Copper Delivery

Delivers copper to enzymes like lysyl oxidase that crosslink collagen fibers, making them stronger - like rebar reinforcing concrete.

Collagen Synthesis

Stimulates fibroblasts to produce more collagen and glycosaminoglycans in lab studies, restoring skin structure and firmness.

Gene Modulation

Modulates expression of 4,000+ genes, resetting DNA activity toward a healthier, more youthful pattern.

Antioxidant Protection

Neutralizes reactive oxygen species and detoxifies lipid peroxidation products, protecting cells from oxidative damage.

Key Research: Pickart L et al. demonstrated gene modulation affecting 4,000+ genes. PMC6073405

Important Limitations

  • Most evidence is for topical cosmetic use, not systemic administration
  • Short plasma half-life (~30 minutes) limits systemic applications
  • Poor skin penetration without advanced delivery systems
  • Plasma levels decline with age: ~200 ng/mL at age 20 to ~80 ng/mL at age 60
  • Not FDA-approved as a drug; regulated as a cosmetic ingredient
i. Wound Healing Cascade
Tissue InjurySPARC releases GHK from collagenGHK-Cu acts as chemoattractantMast cells, macrophages, fibroblasts recruitedCollagen synthesis via TGF-beta pathwayLysyl oxidase crosslinks collagen (Cu2+ required)
Mechanism Copper delivery to lysyl oxidase for collagen crosslinking
Established 12 direct studies
Benefit shown to improve skin firmness and reduce wrinkles
Evidence Level
Moderate
6 Human
4 Animal
8 In Vitro
Mechanism TGF-beta pathway activation promoting fibroblast collagen synthesis
Established 8 direct studies
Benefit shown to accelerate wound healing
Evidence Level
Moderate
4 Human
6 Animal
5 In Vitro
Mechanism Gene expression modulation affecting 4,000+ genes
Supported 3 direct studies
Benefit appears to promote tissue regeneration through gene reprogramming
Evidence Level
Low
2 Animal
4 In Vitro
Mechanism Superoxide dismutase activation and ROS neutralization
Supported 5 direct studies
Benefit may protect against oxidative damage
Evidence Level
Low
1 Human
3 Animal
4 In Vitro
Mechanism Confidence
Established
Supported
Emerging
Evidence Level
High
Moderate
Low
Very Low

Reported positives

  • Improved skin texture and reduced fine lines widely reported
  • Enhanced wound healing and scar reduction
  • Hair growth improvements noted by some users
  • Well-tolerated topically with minimal side effects

Reported negatives

  • Results slow — takes weeks to months for visible effects
  • Topical absorption questioned for deeper tissue effects
  • Product quality varies widely between suppliers
  • Copper peptide staining on fabrics and skin

“Popular in skincare and anti-aging communities. Available both as research peptide and in cosmetic products.”

Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.

NCT ID Title Peptide Phase Status Completion
NCT07437586
Topical GHK-Cu Gel for Acute Skin Wound Healing
Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)
GHK-Cu Phase 2 Recruiting Feb 2027
NCT07437586 Recruiting

Topical GHK-Cu Gel for Acute Skin Wound Healing

GHK-Cu Phase 2 Est. Feb 2027
Phase 01 1
Week 1-2 (Topical)

Based on cosmetic studies: Early effects on skin hydration and texture may begin. Gene expression changes in skin cells occur within days. Initial wound healing acceleration observed in preclinical models.

PMID:26236730
Phase 02 2
Week 2-4 (Topical)

Studies show improvements in skin thickness and collagen production beginning at 2-4 weeks of consistent topical use. Anti-inflammatory effects may reduce skin irritation.

PMID:18644225
Phase 03 3
Week 4-12 (Topical)

Clinical studies showed statistically significant improvements in skin firmness, fine lines, and photodamage after 12 weeks of twice-daily application. Collagen remodeling effects become more apparent.

PMID:18644225
Phase 04 4
Week 12+ (Topical)

Continued use may maintain improvements. Studies suggest ongoing benefits for skin quality. Long-term topical safety appears favorable based on available data.

Research-based observations

This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.

Good Signs (6 indicators)
Blue-colored solution (copper gives characteristic blue color)
Clear solution without particles (topical preparations)
Concentration clearly specified on label (typically 0.01-1%)
Certificate of analysis showing peptide purity and copper content
pH-balanced for skin application
Proper packaging protecting from light degradation
Warning Signs (5 indicators)
Very dark blue or green coloration (may indicate excess copper)
Concentration not specified
No third-party testing verification
Product not specifically formulated for topical use
Unclear if copper is properly chelated to peptide
Bad Signs (7 indicators)
Brown or precipitated solution
Visible particles or cloudiness
No copper color present (should have blue tint)
No certificate of analysis
Skin irritation upon patch testing
Unusual odor
Product labeled for injection when intended for topical use
Positive quality indicator
Requires evaluation
Potential quality issue

For Research Evaluation Only

These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.

Synergistic
Compatible
Caution
Avoid

Complementary wound healing mechanisms - BPC-157 targets systemic tissue repair while GHK-Cu promotes collagen synthesis and skin regeneration.

Both promote tissue repair through different pathways - TB-500 via actin regulation, GHK-Cu via collagen synthesis and copper-dependent enzymes.

Immunomodulatory effects of thymosin alpha-1 may complement GHK-Cu's wound healing properties, particularly in immunocompromised wound healing.

Both peptides are studied for anti-aging effects through different mechanisms - GHK-Cu via collagen/gene expression, epithalon via telomerase.

LL-37

Compatible
Compatible

LL-37's antimicrobial properties may complement GHK-Cu's wound healing effects, providing infection control while tissue regenerates.

Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.

This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.

For complete methodology details, see our Methodology page.

Important Disclaimer

This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.

Get Research Alerts

New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.

No spam. Unsubscribe anytime.

Compare GHK-Cu

Related Peptides

Repair & Recovery

Cartalax

AED peptide · Ala-Glu-Asp · cartilage bioregulator

A synthetic tripeptide (Ala-Glu-Asp) from Vladimir Khavinson's bioregulator framework, proposed to support cartilage tissue repair and chondrocyte function. All research originates from Russian institutes with no independent Western validation or controlled human clinical trials.

See dossier
Repair & Recovery

GHK

Glycyl-Histidyl-Lysine · GHK tripeptide · Liver cell growth factor

A naturally occurring tripeptide (Gly-His-Lys) with copper-binding affinity and wound healing properties. The base form of GHK without added copper. Endogenous to human plasma where it circulates bound to copper. Declines with age. Most research focuses on the copper-complexed form (GHK-Cu), making evidence for GHK alone limited. Primarily relevant as the precursor to GHK-Cu.

See dossier
Repair & Recovery

Sigumir

Cartilage cytamin · Joint peptides · A-6 cartilage peptides

A cytamin-class peptide supplement derived from cartilage tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for joint and cartilage support. Contains peptide complexes rather than defined sequences. No Western clinical validation.

See dossier
Repair & Recovery

TB-500

Thymosin Beta-4 Fragment · TB4-FRAG · TMSB4X

A synthetic fragment of thymosin beta-4 marketed for tissue repair. While the parent compound has Phase 3 clinical research (RGN-259), TB-500 specifically has no published human data.

See dossier

Related Content